Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.
Dyadic is transitioning to a commercial-stage company with modest initial sales, but faces liquidity constraints and slower-than-expected customer adoption despite technical validation from the Gates Foundation and partners.
Dyadic International reported Q3 2026 financial results, highlighting its first direct commercial protein sales and expanded OEM distribution through IBT Bioservices. The company reported a net loss of $1.5M on revenue of $0.7M as it shifts focus toward larger strategic partnerships and licensing arrangements for its C1 and Dapibus production platforms.
Term
Q3 2026
“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors.”
Joe Hazelton, President and Chief Operating Officer
“Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs.”
Joe Hazelton, President and Chief Operating Officer